...
首页> 外文期刊>International Journal of Pharmaceutics >Fixed dose combinations for cardiovascular treatment via coaxial electrospraying: Coated amorphous solid dispersion particles
【24h】

Fixed dose combinations for cardiovascular treatment via coaxial electrospraying: Coated amorphous solid dispersion particles

机译:通过同轴电喷雾器固定剂量组合用于心血管处理:涂层无定形固体分散颗粒

获取原文
获取原文并翻译 | 示例
           

摘要

As a result of an aging population, the need for fixed dose combinations in the treatment of cardiovascular diseases, that are easy to swallow and administer, has been growing remarkably. In this work, the feasibility of coaxial electrospraying (CES) was investigated to manufacture in one single step, a powder of individually coated particles containing atenolol (ATE), lovastatin (LOV) and acetylsalicylic acid (ASA). To improve the dissolution rate of the poorly water soluble LOV, an amorphous solid dispersion (ASD) of LOV with Soluplus (R) (SOL) was formulated and Eudragit S100 (R), an enteric copolymer that only dissolves above pH 7, was applied as coating to avoid LOV hydrolysis in acidic medium. Furthermore, ATE was added to the inner ASD compartment and the acidic ASA was embedded in the coating layer. With regard to the uncoated ASD particles, which were prepared with single nozzle electrospraying, the rate and extent of the LOV dissolution was increased, even to an extent of 100% for the 1/1/6 (ATE/LOV/SOL) ratio. Hence, this ratio was selected and coated particles with proper release of the three APIs could be successfully produced via CES. However, a peculiar behaviour of the coating performance was observed. Regarding LOV, the enteric layer of the particles performed as expected in acidic medium and supersaturation was obtained after the switch to a neutral pH, but in contrast, over 50% of ATE was released after 90 min in acidic medium. Nonetheless, hardly any ATE was released under acidic circumstances from ATE tablets that were, as a benchmark, manually dip-coated with Eudragit S100 (R). Two different model APIs, namely paracetamol (well soluble) and fenofibrate (poorly soluble) were tested as well, revealing similar discrepancy in the coating performance. The coating layer formed during CES is most likely less dense as compared to the layer produced with tablet coating and consequently, more permeable for highly soluble APIs, but not for the poorly soluble compounds.
机译:由于人口老龄化,需要在易于吞咽和施用的心血管疾病治疗中进行固定剂量组合,这一直在增长。在这项工作中,研究了同轴电喷雾(CES)的可行性,在单一步骤中进行制备,含有含有Atenolol(Ate),洛伐他汀(Lov)和乙酰山酸(ASA)的单独涂覆的颗粒的粉末。为了提高水溶性差的溶解速率,配制了与Soluplus(溶胶)的溶解率和eudragit s100(r),仅溶解于溶解于pH7的肠溶性共聚物。作为涂层以避免在酸性介质中的LOV水解。此外,将ATE加入到内部ASD隔室中,将酸性ASA嵌入涂层中。关于用单喷嘴电喷雾制备的未涂覆的ASD颗粒,甚至在1 / 1/6(吃/ LOV /溶胶)比的100%的程度上增加了LOV溶解的速率和程度。因此,选择该比率并通过CE成功地成功地产生具有适当释放的涂覆颗粒。然而,观察到涂层性能的特殊行为。关于LOV,在切换到中性pH之后,在切换到中性pH之后,在酸性培养基中进行预期进行粒子的肠溶层,但相反,在酸性介质中90分钟后释放超过50%的ATE。尽管如此,几乎不会在酸性环境下释放出来的酸性片剂,作为基准,手动浸涂eudragit s100(r)。还测试了两种不同的模型API,即扑热酰胺(良好溶于)和芬橡胶(可溶性差),揭示了涂层性能的类似差异。与用片剂涂层制备的层相比,在CE期间形成的涂层最可能较小,因此对于高度可溶性的API,但不适用于较差的化合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号